

The ASIMOV logo consists of the word "ASIMOV" in a white, sans-serif font. The letter "A" is stylized with a triangular arrowhead pointing upwards and to the right. The letter "V" is also stylized with a triangular arrowhead pointing downwards and to the right.

ASIMOV

BRING COMPUTATION TO LIFE



# Founding team: Four biological engineers




**Alec Nielsen, PhD**

**MIT Biological Engineering**

- Genetic engineer, cell biophysicist, comp. biologist
- Published circuits research in *Science*, *Nature Methods*, *Nature Chemical Biology*

**MIT BE**  
BIOLOGICAL ENGINEERING



**Prof. Chris Voigt, PhD**

**MIT Biological Engineering**

- Synbio pioneer with >80 synbio publications and patents
- Co-director of MIT Syn Bio Center

**MIT-Broad Foundry**  
**MIT BE**  
BIOLOGICAL ENGINEERING



**Raja Srinivas, PhD**

**MIT Biological Engineering**

- Structural biologist, molecular biophysicist, protein engineer
- Founded biotech while in grad school, product entering clinic in 2018

**MIT BE**  
BIOLOGICAL ENGINEERING




**Prof. Doug Densmore, PhD**

**BU Electrical & Computer Engineering**









- >100 design automation publications and patents
- Director of BU Cross-disciplinary Integration of Design Automation Research

**BOSTON**  
UNIVERSITY



# In nature, cells perform tasks using biochemical computation



# Advanced biotechnologies require cell computation



# A programming language for living cells



Science




Genetic circuit design automation

Alec AK Nielsen, et al.

Science 352, 6281 (2016)

ASIMOV

# Our goal is to enable previously impossible biotechnologies



# Therapeutics manufacturing & microbiome applications


## Drug manufacturing pain point

Concurrent growth  
and production

High biochemical  
quality variance

Polygenic metabolic  
burden

Side-product  
accumulation



## Microbial therapeutic pain point

Gene toxicity impacts  
manufacturability


Mismatched  
expression dynamics

Potential microbe  
safety issues

Molecular payload  
delivery in gut

# Next steps: eukaryotic platform development

- Cello is currently for bacteria
- Yeast and CHO cells are more industrially relevant
- Initial validation of platform biochemistry in yeast and CHO cells
- Next step: eukaryote circuit prototypes



The ASIMOV logo consists of the word "ASIMOV" in a white, sans-serif font. The letter "A" is stylized with a triangular arrowhead pointing upwards and to the right. The letter "V" is also stylized with a triangular arrowhead pointing downwards and to the right.

ASIMOV

BRING COMPUTATION TO LIFE

